
Type 1 and type 2 diabetes share a name and a defining feature, high blood sugar, but they are fundamentally different diseases with different causes, different treatments, and different outlooks. Type 2 accounts for roughly 90 to 95% of diabetes cases, while type 1 makes up most of the remainder, but the difference between them matters far more than the numbers suggest.
Type 1 diabetes is an autoimmune condition, meaning the body's own immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. This attack is typically driven by T-cells, a type of immune cell, and researchers can often detect the process happening through specific autoantibodies in the blood, including antibodies against an enzyme called GAD65, among others. Once enough beta cells are destroyed, the body can no longer produce meaningful amounts of insulin on its own.
Type 2 diabetes develops differently, through a combination of insulin resistance, where cells stop responding normally to insulin, and a gradual decline in the pancreas's ability to keep up with the increased insulin demand that resistance creates. Beta cells in type 2 diabetes aren't being destroyed by an autoimmune attack, but they can become progressively exhausted from years of overproducing insulin to compensate for resistance, eventually leading to a real, functional shortage even without any autoimmune process involved.
Type 1 diabetes has historically been most commonly diagnosed in children, teenagers, and young adults, which is part of why it was once called juvenile diabetes, though it can develop at any age, including adulthood. Type 2 diabetes has traditionally been diagnosed in adults, often in midlife or later, though rates among children and teenagers have been rising in recent decades alongside rising childhood obesity rates, a shift significant enough that pediatricians now routinely screen for type 2 diabetes in children with risk factors, something that would have been unusual a generation ago.
Type 1 diabetes tends to develop quickly, often over just weeks, as the immune system rapidly destroys insulin-producing cells, leading to a sudden, sometimes dramatic onset of symptoms like extreme thirst, frequent urination, and rapid weight loss. Because the onset can be so fast, a meaningful number of people, especially children, are first diagnosed during a medical emergency called diabetic ketoacidosis, or DKA, a serious condition where the body, unable to use glucose for energy, starts breaking down fat too quickly and producing acids called ketones that build up to dangerous levels. Recognizing the early warning signs before DKA develops is part of why increased thirst and urination in a child should never be dismissed.
Type 2 diabetes typically develops gradually over years, often preceded by a long period of prediabetes and insulin resistance that produces few or no noticeable symptoms. This slow, quiet progression is part of why type 2 diabetes is so often caught through a routine screening blood test rather than through symptoms prompting someone to see a provider.
Because type 1 diabetes involves a near-total loss of the body's own insulin production, people with type 1 require insulin from diagnosis onward, for life, simply to survive, not just to manage symptoms. Some people do experience what's sometimes called a honeymoon phase shortly after diagnosis, a temporary period where remaining beta cells rally and insulin needs drop, sometimes dramatically, for weeks or months, before the need for insulin increases again as the autoimmune process continues. This phase can be confusing and even give a false sense that the diabetes is resolving, but it is temporary.
People with type 2 diabetes may initially manage their condition with lifestyle changes, oral medications, or non-insulin injectable medications, and some eventually need insulin as the condition progresses, though not universally.
Type 1 diabetes risk is driven primarily by genetic susceptibility combined with an autoimmune trigger that researchers don't fully understand, possibly involving certain viral infections, and it currently cannot be prevented through lifestyle changes. Type 2 diabetes risk is strongly influenced by excess weight, physical inactivity, and family history, which means it's often possible to meaningfully delay or reduce risk through sustained lifestyle changes, even though genetics still plays a real role.
There is currently no way to reverse or put type 1 diabetes into remission, since the underlying insulin-producing cells have been permanently destroyed. Type 2 diabetes, by contrast, can sometimes go into remission, meaning blood sugar returns to a normal range without medication, particularly with significant, sustained weight loss achieved early in the course of the disease.
This isn't just a theoretical possibility. A landmark UK trial called DiRECT, which put participants on a structured low-calorie diet program, found that 46% achieved remission at one year and 36% remained in remission at two years, with remission defined as an A1C below 6.5% while off all diabetes medication. Among the subset who lost and maintained more than 22 pounds, the remission rate reached 81%. A longer follow-up found that remission became harder to sustain over time, with only about 13% still in remission at five years, largely due to gradual weight regain, which underscores that remission is a real, achievable outcome but typically requires ongoing effort to maintain, not a one-time fix.
Not every case fits neatly into one category. Latent autoimmune diabetes in adults, or LADA, is a slow-progressing autoimmune form of diabetes diagnosed in adulthood, typically after age 30, that looks like type 2 diabetes on the surface but is immunologically closer to type 1. People with LADA test positive for the same autoantibodies seen in type 1 diabetes, but unlike classic type 1, they don't need insulin right away, often going six months or more managing on oral medications before their insulin production declines enough to require it.
LADA is thought to account for somewhere between 2% and 12% of adults initially diagnosed with type 2 diabetes, meaning a meaningful share of people carrying a type 2 label may actually have this in-between form. Misclassifying LADA as ordinary type 2 diabetes can lead to delayed insulin therapy and poorer blood sugar control in the meantime, which is part of why providers sometimes order autoantibody testing in adults who don't fit the typical type 2 profile, for example, someone who is lean, has a strong personal or family autoimmune history, or responds poorly to standard oral medications.
In classic cases, age and how quickly symptoms appeared make the type fairly obvious. When it isn't, providers can order autoantibody testing, the same GAD65 and related antibodies associated with type 1 and LADA, along with a test called C-peptide, which measures how much insulin your own pancreas is still producing. Low C-peptide alongside positive autoantibodies points toward an autoimmune process, whether classic type 1 or LADA, while normal or high C-peptide without autoantibodies points toward type 2.
Confusing type 1 and type 2 diabetes can lead to real misunderstandings, including the mistaken belief that type 1 diabetes results from diet or lifestyle choices, which it does not. Getting the type right also has direct treatment consequences: someone with unrecognized LADA or type 1 who is treated as though they have straightforward type 2 diabetes may go without insulin longer than they should, allowing blood sugar to stay elevated and increasing the risk of complications in the meantime. Understanding which type you or a loved one has shapes everything from daily management to long-term expectations.
Questions about your own diabetes risk or diagnosis? CareArc's primary care team can help you understand your specific situation. Request an appointment to get started.